Literature DB >> 17522277

Validation and reproducibility assessment of tigecycline MIC determinations by Etest.

Anne Bolmström1, Asa Karlsson, Anette Engelhardt, Phion Ho, Peter J Petersen, Patricia A Bradford, C Hal Jones.   

Abstract

A multicenter study was conducted to validate Etest tigecycline compared to the Clinical Laboratory Standards Institute reference broth microdilution and agar dilution methodologies. A large collection of gram-negative (n = 266) and gram-positive (n = 162) aerobic bacteria, a collection of anaerobes (n = 385), and selected collections of nonpneumococcal streptococci (n = 369), Streptococcus pneumoniae (n = 372), and Haemophilus influenzae (n = 372) were tested. Strains with reduced susceptibility to tigecycline were used with all test methods. The Etest showed excellent inter- and intralaboratory reproducibility for all organism groups tested regardless of the test methodology. The essential agreement values with the reference method (+/-1 dilution) were >99% for the collection of gram-negative and gram-positive aerobes; >98% for the S. pneumoniae, H. influenzae, and anaerobe collections; and 100% for the group of nonpneumococcal streptococci. These results validate the performance accuracy and utility of Etest tigecycline and verify the reproducibility of this convenient predefined gradient methodology for tigecycline susceptibility determination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522277      PMCID: PMC1951261          DOI: 10.1128/JCM.00089-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Evaluation of the E test, a novel method of quantifying antimicrobial activity.

Authors:  D F Brown; L Brown
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

2.  Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.

Authors:  C N Baker; S A Stocker; D H Culver; C Thornsberry
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

Authors:  Timothy Babinchak; Evelyn Ellis-Grosse; Nathalie Dartois; Gilbert M Rose; Evan Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

5.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

6.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

7.  In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Brian M Johnson; Jack L Johnson; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

8.  Evaluation of the E test for susceptibility testing of anaerobic bacteria.

Authors:  D M Citron; M I Ostovari; A Karlsson; E J Goldstein
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

Authors:  Takahiro Hirata; Asami Saito; Kunihiko Nishino; Norihisa Tamura; Akihito Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 10.  Tetracycline therapy: update.

Authors:  Marilyn C Roberts
Journal:  Clin Infect Dis       Date:  2003-01-28       Impact factor: 9.079

View more
  12 in total

1.  First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species.

Authors:  R P Rennie; L Turnbull; C Brosnikoff; J Cloke
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Authors:  Teresa Spanu; Giulia De Angelis; Michela Cipriani; Barbara Pedruzzi; Tiziana D'Inzeo; Maria Adriana Cataldo; Gabriele Sganga; Evelina Tacconelli
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

3.  In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.

Authors:  R Naesens; J P Ursi; J Van Schaeren; A Jeurissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-19       Impact factor: 3.267

4.  Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.

Authors:  Londa J Berghaus; Steeve Giguère; Kristen Guldbech; Eleanor Warner; Ukachi Ugorji; Roy D Berghaus
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

5.  Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens.

Authors:  Olympia Zarkotou; Spyros Pournaras; George Altouvas; Vassiliki Pitiriga; Maria Tziraki; Vassiliki Mamali; Katerina Themeli-Digalaki; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2012-08-29       Impact factor: 5.948

6.  Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC.

Authors:  M Torrico; N González; M J Giménez; L Alou; D Sevillano; D Navarro; M P Díaz-Antolín; N Larrosa; L Aguilar; N Garcia-Escribano
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

Review 7.  Antimicrobial Susceptibility Testing for Enterococci.

Authors:  Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias
Journal:  J Clin Microbiol       Date:  2022-06-13       Impact factor: 11.677

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology.

Authors:  Y Glupczynski; C Berhin; H Nizet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-17       Impact factor: 3.267

10.  In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.

Authors:  Chris M Pillar; Deborah C Draghi; Michael J Dowzicky; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.